UK's Second Ebola Vaccine Ready For Testing

The video discusses a trial for the UK's second Ebola vaccine, involving 87 volunteers. It highlights the trial's double dose nature and the small risks involved. The video also covers global efforts in developing Ebola vaccines, with candidates in the UK, Russia, China, and the US. The World Health Organization emphasizes the benefits of competition in vaccine development, potentially leading to better prices and improved epidemic responses. The trial is part-funded by the EU and is set for fast-tracked testing in Africa.

What is the purpose of the trial mentioned in the text?

How many volunteers are involved in the trial?

What are the potential benefits of having multiple Ebola vaccines developed?

What does the World Health Organization suggest about competition among vaccine manufacturers?

What challenges does the unpredictability of Ebola outbreaks present?